Oxford Biomedica plc (LON:OXB - Get Free Report) shares passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of GBX 372.36 ($4.94) and traded as low as GBX 295 ($3.92). Oxford Biomedica shares last traded at GBX 304 ($4.04), with a volume of 483,197 shares trading hands.
Oxford Biomedica Stock Performance
The firm has a market capitalization of £313.59 million, a price-to-earnings ratio of -2.19 and a beta of 1.09. The company has a 50-day moving average price of GBX 291.76 and a 200-day moving average price of GBX 369.95. The company has a quick ratio of 1.67, a current ratio of 2.35 and a debt-to-equity ratio of 166.48.
Oxford Biomedica (LON:OXB - Get Free Report) last announced its quarterly earnings results on Wednesday, April 9th. The biopharmaceutical company reported GBX (41.75) (($0.55)) earnings per share (EPS) for the quarter. Oxford Biomedica had a negative return on equity of 202.50% and a negative net margin of 145.98%. As a group, equities research analysts forecast that Oxford Biomedica plc will post -31.0799998 earnings per share for the current year.
About Oxford Biomedica
(
Get Free Report)
Oxford Biomedica LSE: OXB is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies.
Featured Articles
Before you consider Oxford Biomedica, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oxford Biomedica wasn't on the list.
While Oxford Biomedica currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
